OakChart

Olema Pharmaceuticals Inc

OLMAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

8.04+0.77 (10.59%)
2026-11-11 22:20 CET
Market cap
636.11 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-235.95 USD m
Free cash flow, TTM
-178.44 USD m
EPS diluted, TTM
-2.35
P/E
-
Compare

Price

OLMA against its 20, 50 and 200-day averages
2050200missearnings
10.0015.002.8M5.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OLMAclose 8.0420-day 7.1250-day 8.31200-day 13.268.0452w low

77.8% under the 52-week high of 36.26 on 16 Dec 2025. 52-week low 6.24 on 23 Oct 2026. Last 15 sessions, 32.4% high to low

Volume 1.48× normal · the line is the 50-bar volume average

Profile

OLMA
52-week range, 6% of the way up
6.2436.26

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

IndexRUT
Employees131
IPONov 19, 2020
Beta2.02
ATR, 14d0.57
Rel volume1.48
Short float24.36%
Insider own19.66%
Inst own101.22%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap703.48M
Enterprise Value293.07M
Income-235.95M
Sales0.00M
Book/sh4.21
Cash/sh4.73
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees131
IPONov 19, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.91
P/C1.70
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.12
Current Ratio6.12
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.35
EPS next Y-2.90
EPS next Q-0.75
EPS this Y-39.26%
EPS next Y-11.30%
EPS next 5Y-9.73%
EPS past 3/5Y10.68% -25.06%
Sales past 3/5Y- -
EPS Y/Y TTM-29.91%
Sales Y/Y TTM-
EPS Q/Q-47.85%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.-14.64% -

Ownership

Insider Own19.66%
Insider Trans-0.15%
Inst Own101.22%
Inst Trans0.47%
ROA-59.47%
ROE-69.77%
ROIC-63.45%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2012.85%
SMA50-3.29%
SMA200-39.37%
Trades-

Technical

Shs Outstand87.54M
Shs Float70.29M
Short Float24.36%
Short Ratio13.91
Short Interest17.12M
52W High36.26 -77.83%
52W Low6.24 28.95%
Volatility8.13% 7.31%
ATR (14)0.57
RSI (14)56.14
Beta2.02
Rel Volume1.48
Avg Volume1.23M
Volume1,819,463

Performance

Perf Week6.63%
Perf Month14.53%
Perf Quarter-23.50%
Perf Half Y-40.80%
Perf YTD-67.84%
Perf Year-1.83%
Perf 3Y-49.21%
Perf 5Y-70.32%
Perf 10Y-
Recom1.17
Target Price36.00
Prev Close7.27
Price8.04
Change %10.59%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Mar 27, 2026InitiatedWWolfe ResearchPeer Perform
Mar 19, 2026ResumedJJefferiesBuy
Feb 11, 2026InitiatedSStifelBuy$48+497.0%
Jan 07, 2026InitiatedPPiper SandlerOverweight$40+397.5%
Oct 08, 2025InitiatedGGuggenheimBuy$20+148.8%
Aug 12, 2025ReiteratedCCitigroupBuy$20 → $21+161.2%
Apr 02, 2024InitiatedGGoldmanBuy$24+198.5%
Jan 30, 2024InitiatedCCitigroupBuy$20+148.8%
Jul 21, 2023InitiatedOOppenheimerOutperform$21+161.2%
May 05, 2023InitiatedCCapitalOneOverweight$16+99.0%

Peers

Mkt cap
TickerCompanyMkt cap
ARVNArvinas Inc452.51M
CELCCelcuity Inc3.16B
RLAYRelay Therapeutics Inc4.36B
LLYLilly(Eli) & Co1352.12B
AZNAstrazeneca plc287.66B
PFEPfizer Inc167.86B
ATOSAtossa Therapeutics Inc20.26M
IDYAIdeaya Biosciences Inc3.16B
ELVNEnliven Therapeutics Inc3.77B
NVSNovartis AG ADR293.47B

Insider trading

latest 14 of 54
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Harmon CyrusDirectorJul 24 '26Sale11.7112,500146,425702,770Jul 27 07:30 PM
Harmon CyrusDirectorJul 23 '26Sale11.5812,500144,738715,270Jul 27 07:30 PM
Harmon CyrusDirectorJul 24 '26Proposed Sale11.7112,500146,419Jul 24 03:11 PM
Harmon CyrusDirectorJul 23 '26Proposed Sale11.5812,500144,738Jul 23 02:23 PM
Kovacs Shane William CharlesFormer OfficerMar 16 '26Proposed Sale16.614,16669,178Mar 16 04:03 PM
Kovacs Shane William CharlesFormer OfficerMar 16 '26Proposed Sale16.08100,0001,607,719Mar 16 12:43 PM
Kovacs Shane William CharlesFormer OfficerMar 11 '26Proposed Sale15.9450,000796,796Mar 11 04:20 PM
Kovacs Shane William CharlesFormer OfficerMar 10 '26Proposed Sale17.0053,206904,566Mar 10 12:27 PM
Kovacs Shane William CharlesFormer OfficerMar 09 '26Proposed Sale13.45241,9993,254,933Mar 09 03:16 PM
Mitchell ShawnteCHIEF LEGAL OFFICERMar 04 '26Option Exercise4.3725,000109,25025,000Mar 05 08:00 PM
Mitchell ShawnteCHIEF LEGAL OFFICERMar 03 '26Option Exercise4.3715,00065,55015,000Mar 05 08:00 PM
Mitchell ShawnteCHIEF LEGAL OFFICERMar 04 '26Sale24.2525,000606,3530Mar 05 08:00 PM
Mitchell ShawnteCHIEF LEGAL OFFICERMar 03 '26Sale23.0115,000345,1500Mar 05 08:00 PM
Kovacs Shane William CharlesFormer OfficerMar 04 '26Proposed Sale24.4320,000488,654Mar 04 02:19 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 200
  • Olema Oncology Reports Third Quarter 2026 Financial and Operating Results (GlobeNewswire)
  • Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium (GlobeNewswire) -10.34%
  • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results (InvestorsHub)
  • Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump (Investing.com)
  • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Olema Oncology Appoints Jason O'Byrne as Chief Financial Officer (GlobeNewswire)
  • Olema Oncology Reports Second Quarter 2026 Financial and Operating Results (GlobeNewswire) -12.65%
  • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -15.89%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.730-0.637-0.7290.000.0011
2026Q22026-08-10-0.610-0.552-0.6050.000.0010
2026Q12026-05-12-0.520-0.531-0.5160.000.0012
2025Q42026-03-16-0.500-0.514-0.5040.000.0012
2025Q32025-11-10-0.490-0.475-0.4920.000.009
2025Q22025-08-11-0.510-0.376-0.5120.000.007
2025Q12025-05-13-0.360-0.485-0.3560.000.004
2024Q42025-03-18-0.510-0.636-0.4520.000.007
2024Q32024-11-12-0.600-0.571-0.6030.000.008
2024Q22024-08-06-0.540-0.543-0.5400.000.009
2024Q12024-05-08-0.560-0.539-0.5570.000.008
2023Q42024-03-11-0.490-0.481-0.4890.000.009
2023Q32023-11-07-0.480-0.512-0.4780.000.008
2023Q22023-08-08-0.490-0.727-0.4940.000.007
2023Q12023-05-09-0.700-0.663-0.7010.000.006
2022Q42023-03-09-0.650-0.652-0.6510.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-3.150-0.983-0.6100.000.00
2021FY-1.800-1.690-1.7990.000.00
2022FY-2.620-2.671-2.6200.000.00
2023FY-2.140-2.117-2.1360.000.00
2024FY-2.200-2.300-2.2040.000.00
2025FY-1.870-1.891-1.8690.000.00
2026FY--2.604--0.00
2027FY--2.899--8.19
2028FY--2.471--85.43
2029FY--1.883--202.01
2030FY--0.623--393.01

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-107000.000.000.00
2026Q4S2026-08-117000.000.000.00
2026Q4S2026-06-117000.000.000.00
2026Q4S2026-05-128001.560.0012.50
2026Q4S2026-03-168001.560.0012.50
2026Q4S2026-02-096002.080.0012.50
2026Q4S2026-02-065002.500.0012.50
2026Q4S2025-11-114003.130.0012.50
2026Q4S2025-11-104003.130.0012.50
2026Q4R2026-11-10402-0.69-0.75-0.64
2026Q4R2026-10-26400-0.65-0.70-0.64
2026Q4R2026-10-25401-0.65-0.70-0.64
2026Q4R2026-08-12404-0.65-0.70-0.64
2026Q4R2026-08-11403-0.64-0.70-0.56

Estimate history

EPS, annual-0.059-0.107-0.61-1.799-2.62-2.136-2.204-1.867-2.3539
Period20182019202020212022202320242025TTM
EPS, quarterly-0.603-0.452-0.356-0.512-0.492-0.504-0.516-0.605-0.728
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual37.5240.1739.30839.79740.28754.99374.31381.37687.538
Period20182019202020212022202320242025MRQ
Shares, quarterly57.28874.31368.33368.62868.65381.37687.33387.45287.538
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.500.490.390.381.661.660.010.010.01
Gross Profit-0.50-0.49-0.39-0.38-1.66-1.66-0.01-0.01-0.01
Selling, General and Administrative Excl. Other252.27178.21141.87104.58105.3369.8321.524.312.07
Research and Development217.84157.70124.5286.1482.2751.1013.703.921.69
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-252.77-178.70-142.26-104.96-106.99-71.49-21.53-4.32-2.08
Interest Expense--0.000.000.000.000.650.000.03
Unusual Expense0.000.000.000.000.000.000.000.000.09
Net Income Before Taxes-235.95-162.45-129.47-96.66-104.79-71.10-22.12-4.32-2.20
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-235.95-162.45-129.47-96.66-104.79-71.10-22.12-4.32-2.20
Net Income From Continuing Operations-235.95-162.45-129.47-96.66-104.79-71.10-22.12-4.32-2.20
Net Income-235.95-162.45-129.47-96.66-104.79-71.10-23.99-4.32-2.20
EPS (Recurring)-2.33-1.87-2.20-2.14-2.62-1.80-0.61-0.11-0.06
EPS (Basic, Before Extraordinaries)-2.35-1.87-2.20-2.14-2.62-1.80-0.61-0.11-0.06
EPS (Diluted)-2.35-1.87-2.20-2.14-2.62-1.80-0.61-0.11-0.06
EBITDA-252.27-178.21-141.87-104.58-105.33-69.83-21.52-4.31-2.07
Non-Operating Income (Expense)16.8216.2512.788.312.200.400.060.010.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense39.4017.5922.5817.2618.8315.913.080.000.00
Shares Outstanding87.5481.3874.3154.9940.2939.8039.3140.1737.52
Market Capitalization636.11636.11334.05768.4299.12377.091,852.031,878.22-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.090.100.120.190.040.130.130.12
Gross Profit-0.09-0.10-0.12-0.19-0.04-0.13-0.13-0.12
Selling, General and Administrative Excl. Other77.4367.0857.8749.9045.8347.7334.7436.65
Research and Development67.6057.7849.2343.2239.9543.9030.6232.30
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-77.53-67.18-57.99-50.08-45.88-47.86-34.87-36.77
Interest Expense------0.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-73.60-63.20-53.09-46.06-42.22-43.78-30.39-33.57
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-73.60-63.20-53.09-46.06-42.22-43.78-30.39-33.57
Net Income From Continuing Operations-73.60-63.20-53.09-46.06-42.22-43.78-30.39-33.57
Net Income-73.60-63.20-53.09-46.06-42.22-43.78-30.39-33.57
EPS (Recurring)-0.73-0.61-0.52-0.50-0.49-0.51-0.36-0.45
EPS (Basic, Before Extraordinaries)-0.73-0.60-0.52-0.50-0.49-0.51-0.36-0.45
EPS (Diluted)-0.73-0.60-0.52-0.50-0.49-0.51-0.36-0.45
EBITDA-77.43-67.08-57.87-49.90-45.83-47.73-34.74-36.65
Non-Operating Income (Expense)3.933.984.904.023.664.084.483.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.0812.9010.154.274.254.694.386.32
Shares Outstanding87.5487.4587.3381.3868.6568.6368.3374.31
Market Capitalization636.111,092.721,299.511,966.50671.93291.47256.93334.05

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments505.44434.09261.81204.42287.25338.550.073.15
Short Term Receivables4.062.120.670.320.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets5.962.274.034.163.443.590.040.09
Total Current Assets515.45438.47266.51208.90290.69342.140.103.24
Net Property, Plant & Equipment1.422.063.263.984.720.070.030.03
Total Investments and Advances0.000.000.000.000.000.000.000.00
Long-Term Note Receivable--7.17-----
Intangible Assets0.890.680.00-----
Deferred Tax Assets143.89105.09------
Other Assets15.679.760.002.770.540.510.000.00
Total Assets677.32556.07276.94215.65295.94342.720.133.27
Short Term Debt Incl. Current Port. of LT Debt1.121.170.991.010.930.000.000.00
Accounts Payable9.254.462.700.370.000.720.940.12
Income Tax Payable-0.04------
Other Current Liabilities41.4236.0917.9315.168.093.870.440.09
Total Current Liabilities51.8041.7621.6216.559.024.581.380.20
Long Term Debt3.070.261.431.552.360.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities143.89105.09------
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities198.76147.1023.0518.1011.384.581.380.20
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.009.359.35
Common Equity478.56408.96253.90197.55284.57338.14-10.59-6.28
Total Shareholders Equity478.56408.96253.90197.55284.57338.14-1.253.07
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity478.56408.96253.90197.55284.57338.14-1.253.07
Total Liabilities & Stockholders Equity677.32556.07276.94215.65295.94342.720.133.27
Book Value Per Share5.885.504.624.907.158.60-0.26-0.17
Tangible Book Value Per Share5.875.494.624.907.158.60-0.26-0.17
Full-Time Employees131967486743710-
Price to Book Ratio1.731.682.780.451.315.59-81.79-
Return on Assets-26.34-31.09-39.24-40.97-22.26-12.90-253.66-
Return on Equity-36.61-39.07-42.82-43.47-22.83-13.13-473.25-
Return on Invested Capital-33.73-31.64-37.86-52.63-24.78-6.54--71.56
Quick Ratio9.9510.5012.3312.6232.2374.620.0716.13
Current Ratio9.9510.5012.3312.6232.2374.620.0716.13

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-235.95-162.45-129.47-96.66-104.79-71.10-22.12-4.32-2.20
Depreciation0.500.490.390.381.661.660.010.010.01
Other Funds (Non Cash)36.1712.4715.5713.1418.0415.913.750.000.12
Funds from Operations-199.27-149.49-113.52-83.14-85.09-53.52-18.36-4.31-2.07
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital21.952.779.16-0.593.022.83-1.501.23-0.11
Cash from Operating Activities-177.32-146.72-104.35-83.73-82.06-50.69-19.87-3.08-2.18
Capital Expenditures-1.120.00-0.160.00-0.36-1.57-0.060.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.050.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-70.14-155.76-93.37-4.8791.84-273.860.000.000.00
Purchase of Investments-422.31-500.72-394.96-255.62-213.66-486.970.000.000.00
Sale Or Maturity of Investments352.16344.96301.59250.76305.50213.100.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.010.000.000.000.000.00
Cash from Investing Activities-71.21-155.76-93.53-4.8591.48-275.44-0.060.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock260.80208.30268.82133.410.481.39355.310.005.25
Repurchase of Common Pref Stock0.000.000.000.000.000.00-2.290.000.00
Sale of Common Pref Stock260.80208.30268.82133.410.481.39357.600.005.25
Proceedsfrom Stock Options248.24199.91267.15130.790.330.72356.960.005.25
Issuance or Reduction of Debt, Net0.003.000.000.000.000.003.090.000.00
Change in Long Term Debt0.003.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.003.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities260.80211.30268.82133.410.481.39358.400.005.25
Net Change in Cash12.26-91.1870.9444.849.89-324.74338.48-3.083.08
Free Cash Flow-178.44-146.72-104.51-83.73-82.43-52.27-19.92-3.08-2.18
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments413.77461.07505.35505.44328.96361.91
Short Term Receivables3.373.173.354.062.972.75
Inventories0.000.000.000.000.000.00
Other Current Assets6.285.644.535.962.403.07
Total Current Assets423.43469.88513.23515.45334.33367.73
Net Property, Plant & Equipment2.001.021.281.421.912.25
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.730.780.840.891.020.80
Deferred Tax Assets---143.89--
Other Assets14.9214.9015.3015.6715.2011.23
Total Assets441.07486.58530.64677.32352.45382.00
Short Term Debt Incl. Current Port. of LT Debt0.360.660.961.121.171.15
Accounts Payable1.211.673.729.253.470.93
Income Tax Payable-0.02---0.00
Other Current Liabilities67.6750.6742.4941.4237.0131.08
Total Current Liabilities69.2353.0147.1751.8041.6633.16
Long Term Debt3.003.003.003.073.313.60
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---143.89--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities72.2356.0150.17198.7644.9736.77
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity368.84430.56480.48478.56307.49345.24
Total Shareholders Equity368.84430.56480.48478.56307.49345.24
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity368.84430.56480.48478.56307.49345.24
Total Liabilities & Stockholders Equity441.07486.58530.64677.32352.45382.00
Book Value Per Share4.214.925.505.884.485.03
Tangible Book Value Per Share4.214.915.495.874.465.02
Full-Time Employees---131-117
Price to Book Ratio1.732.272.545.581.740.76
Return on Assets-59.47-47.10-39.38-26.34-51.48-44.71
Return on Equity-69.77-52.74-42.86-36.61-59.22-49.72
Return on Invested Capital-19.79-14.58-10.98-9.56-13.58-12.55
Quick Ratio6.128.8610.889.958.0311.09
Current Ratio6.128.8610.889.958.0311.09

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-73.60-63.20-53.09-46.06-42.22-43.78
Depreciation0.090.100.120.190.040.13
Other Funds (Non Cash)11.6111.989.183.413.233.27
Funds from Operations-61.90-51.12-43.79-42.46-38.95-40.38
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital14.795.22-2.194.144.4210.50
Cash from Operating Activities-47.11-45.90-45.99-38.33-34.53-29.88
Capital Expenditures-0.90-0.220.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.050.000.000.000.000.00
Purchase or Sale of Investments46.4541.064.53-162.1817.2734.23
Purchase of Investments-50.77-48.24-69.94-253.35-71.65-32.86
Sale Or Maturity of Investments97.2289.3074.4791.1788.9267.10
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities45.6040.844.53-162.1817.2734.23
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.43-3.3050.11213.550.04-5.52
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.43-3.3050.11213.550.04-5.52
Proceedsfrom Stock Options0.000.8941.68205.670.00-5.75
Issuance or Reduction of Debt, Net0.000.000.000.000.003.00
Change in Long Term Debt0.000.000.000.000.003.00
Issuance of Long Term Debt0.000.000.000.000.003.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.004.41-4.410.000.000.00
Other Financing Activities Uses0.004.41-4.410.000.000.00
Cash from Financing Activities0.431.1145.70213.550.04-2.52
Net Change in Cash-1.08-3.954.2513.04-17.211.83
Free Cash Flow-48.01-46.12-45.99-38.33-34.53-29.88

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3024.36%17.1M70.3M1.18M
2026-10-1522.31%15.7M70.3M1.09M
2026-09-3020.91%14.7M70.3M1.11M
2026-09-1522.86%16.1M70.3M1.27M
2026-08-3122.28%15.7M70.3M1.38M
2026-08-1422.50%15.8M70.3M1.43M
2026-07-3122.53%16.0M70.8M1.43M
2026-07-1521.32%15.1M70.8M1.43M
2026-06-3019.82%14.0M70.8M1.35M
2026-06-1518.14%12.8M70.8M1.29M
2026-05-2915.89%11.9M75.1M1.48M
2026-05-1516.41%11.6M70.6M1.48M
2026-04-3018.86%13.0M69.2M1.56M
2026-04-1518.70%12.9M69.2M1.60M
2026-03-3117.91%12.3M68.5M1.69M
2026-03-1312.03%8.2M68.5M1.73M
2026-02-2713.36%8.3M61.8M1.78M
2026-02-1314.56%9.0M61.8M3.83M
2026-01-3015.33%10.1M66.0M3.73M
2026-01-1513.79%9.1M66.0M3.82M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.003.508.400.000.0000.000.000.984-0.0150.001
call3.002.506.900.0014.9620.000.000.977-0.0150.001
call4.001.656.400.0012.8550.000.000.969-0.0140.001
call5.000.504.900.008.5040.000.000.933-0.0220.002
call6.000.004.900.0011.9250.000.000.726-0.0720.004
call7.000.004.900.7310.37912.000.000.707-0.1060.004
call8.000.301.300.572.58254.008.000.599-0.0840.005
call9.000.001.700.063.3212520.000.517-0.0940.005
call10.000.002.301.093.8891230.000.477-0.1100.005
call11.000.004.900.155.78167.000.000.495-0.1440.005
call12.000.004.900.166.1271910.000.482-0.1530.005
call13.000.004.900.056.47122.000.000.472-0.1600.005
call14.000.004.900.056.75955.000.000.463-0.1670.004
call15.000.004.900.007.0000.000.000.456-0.1730.005
call16.000.004.900.007.2370.000.000.449-0.1790.004
call17.000.004.900.007.4740.000.000.444-0.1840.004
call18.000.004.900.037.6741.000.000.439-0.1880.004
put2.000.000.050.004.6340.000.00-0.019-0.0130.001
put3.000.004.900.007.1490.000.00-0.090-0.0720.002
put4.000.000.050.055.2891190.00-0.130-0.0700.002
put5.000.000.100.053.87434.000.00-0.181-0.0640.003
put6.000.000.900.107.4921210.00-0.220-0.1340.004
put7.000.001.500.504.3311100.00-0.293-0.1050.004
put8.000.001.701.403.50847.000.00-0.401-0.0840.005
put9.000.004.902.559.04318.000.00-0.483-0.0930.005
put10.000.504.900.007.2710.000.00-0.567-0.0910.005
put11.001.505.504.306.88260.000.00-0.597-0.1020.005
put12.002.506.500.007.2770.000.00-0.568-0.1310.005
put13.003.507.500.007.6240.000.00-0.583-0.1400.005
put14.004.508.500.007.9330.000.00-0.594-0.1470.005
put15.005.509.500.008.2120.000.00-0.604-0.1530.005
put16.006.5010.500.008.4650.000.00-0.612-0.1590.005
put17.007.5011.500.008.6980.000.00-0.619-0.1640.005
put18.008.5012.500.008.9120.000.00-0.625-0.1690.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-16SCHEDULE 13D/ASEC
2026-10-158-KCurrent report2026-10-12SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-133Initial statement of beneficial ownership of securities2026-08-11SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-06SCHEDULE 13G/ASEC
2026-07-29SCHEDULE 13G/ASEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-24144Filing for proposed sale of securities under Rule 144.SEC
2026-07-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-238-KCurrent report2026-06-17SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-05-268-KCurrent report2026-05-26SEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-0700291.16K2
2026-060000
2026-050000
2026-040000
2026-0300951.50K2
2026-020000
2026-01006.46M7
2025-120017.04M6
2025-110000

Institutional holders

Manager% owned
FMR LLC13.09%
Paradigm Biocapital Advisors LP9.93%
Jupiter Topco LLC8.12%
Bain Capital Life Sciences Investors, LLC8.11%
BlackRock, Inc.7.69%
BVF INC/IL6.06%
Siren, L.L.C.5.56%
STATE STREET CORP4.94%
VANGUARD CAPITAL MANAGEMENT LLC3.83%
Logos Global Management LP3.67%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.11%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.99%
iShares Russell 2000 ETF2.34%
Select Health Care Portfolio1.92%
Strategic Advisers Fidelity U.S. Total Stock Fund1.88%
Fidelity Stock Selector Small Cap Fund1.04%
Fidelity Small Cap Index Fund0.98%
Fidelity Advisor Health Care Fund0.94%
Fidelity Advisor Biotechnology Fund0.89%
Franklin Small Cap Growth Fund0.79%

OakChart. OLMA. Cached 15 minutes.